Published in Psychopharmacology (Berl) on December 08, 2011
Mechanisms underlying the neuroprotective effect of brain reserve against late life depression. J Neural Transm (Vienna) (2014) 1.07
3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. Proc Natl Acad Sci U S A (2012) 0.83
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol (2014) 0.80
Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms. Int J Neuropsychopharmacol (2016) 0.79
Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci (2015) 0.79
Dietary DHA during development affects depression-like behaviors and biomarkers that emerge after puberty in adolescent rats. J Lipid Res (2014) 0.78
A novel approach to contrast-induced nephrotoxicity: the melatonergic agent agomelatine. Br J Radiol (2016) 0.75
Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice. Sci Rep (2017) 0.75
Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine. BMC Neurosci (2014) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Dynamic instability of microtubule growth. Nature (1984) 20.32
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res (1988) 7.29
Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci (2009) 4.13
Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) (1995) 3.61
Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron (2009) 3.54
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev (2005) 3.32
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus (2006) 3.02
Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc Natl Acad Sci U S A (1997) 2.77
The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol (2010) 2.64
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry (2008) 2.52
Role of neurotrophic factors in depression. Curr Opin Pharmacol (2006) 2.39
Cell biology: Tubulin acetylation and cell motility. Nature (2003) 2.10
Differences in the cellular distributions of two microtubule-associated proteins, MAP1 and MAP2, in rat brain. J Neurosci (1984) 2.08
Tubulin post-translational modifications: encoding functions on the neuronal microtubule cytoskeleton. Trends Neurosci (2010) 2.00
Activity-dependent dynamic microtubule invasion of dendritic spines. J Neurosci (2008) 1.98
Enhanced stability of microtubules enriched in detyrosinated tubulin is not a direct function of detyrosination level. J Cell Biol (1988) 1.96
PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses. J Neurosci (1996) 1.95
Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry (2007) 1.80
Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog Neurobiol (2000) 1.76
A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments. J Psychopharmacol (2011) 1.72
Antidepressants and neuroplasticity. Bipolar Disord (2002) 1.66
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol (2007) 1.64
HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One (2010) 1.63
Hippocampal synapses depend on hippocampal estrogen synthesis. J Neurosci (2004) 1.60
Accumulation of delta 2-tubulin, a major tubulin variant that cannot be tyrosinated, in neuronal tissues and in stable microtubule assemblies. J Cell Sci (1994) 1.59
Polysialylated neural cell adhesion molecule promotes remodeling and formation of hippocampal synapses. J Neurosci (2004) 1.53
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry (2006) 1.53
Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev (2006) 1.51
Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull (2001) 1.49
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov (2010) 1.47
Control of neuronal polarity and plasticity--a renaissance for microtubules? Trends Cell Biol (2009) 1.40
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther (2003) 1.40
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol (2002) 1.30
Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment. Psychopharmacology (Berl) (2008) 1.21
Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther (2000) 1.18
Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs (2010) 1.14
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2009) 1.12
New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.11
Immunocytochemical analysis of synaptic proteins provides new insights into diabetes-mediated plasticity in the rat hippocampus. Neuroscience (2005) 1.10
Deletion of the N-terminus of murine map2 by gene targeting disrupts hippocampal ca1 neuron architecture and alters contextual memory. Neuroscience (2003) 1.09
Chronic antidepressant treatment prevents accumulation of gsalpha in cholesterol-rich, cytoskeletal-associated, plasma membrane domains (lipid rafts). Neuropsychopharmacology (2005) 1.07
Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus. Eur J Neurosci (2006) 1.05
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) (2004) 1.05
Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res (2002) 1.05
Remodeling of neuronal networks by stress. Front Biosci (2006) 1.03
Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology (2009) 1.01
Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs (2009) 1.01
Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology (2002) 1.01
Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol (2009) 1.01
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) (2008) 1.00
Genomic structure of human microtubule-associated protein 2 (MAP-2) and characterization of additional MAP-2 isoforms. Proc Natl Acad Sci U S A (1995) 0.99
Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience (2010) 0.98
Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology (Berl) (2000) 0.96
Dentate gyrus is necessary for disambiguating similar object-place representations. Learn Mem (2010) 0.96
Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol (2011) 0.95
Cytoskeletal changes in the hippocampus following restraint stress: role of serotonin and microtubules. Synapse (2003) 0.95
cAMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol (1989) 0.94
Neuronal plasticity, stress and depression: involvement of the cytoskeletal microtubular system? Curr Drug Targets CNS Neurol Disord (2005) 0.92
Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacol Biochem Behav (2002) 0.92
Region-specific involvement of BDNF secretion and synthesis in conditioned taste aversion memory formation. J Neurosci (2011) 0.91
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci (2004) 0.91
Cytoskeletal alterations in rat hippocampus following chronic unpredictable mild stress and re-exposure to acute and chronic unpredictable mild stress. Behav Brain Res (2009) 0.91
Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology (Berl) (2011) 0.90
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.89
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol (2006) 0.89
Differential expression of molecular markers of synaptic plasticity in the hippocampus, prefrontal cortex, and amygdala in response to spatial learning, predator exposure, and stress-induced amnesia. Hippocampus (2011) 0.88
The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol (2008) 0.87
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol (2005) 0.87
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol (2006) 0.86
Experience-dependent modifications in MAP2 phosphorylation in rat olfactory bulb. J Neurosci (1997) 0.86
Changes of MAP2 phosphorylation during brain development. J Histochem Cytochem (1995) 0.86
Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol Biochem Behav (2011) 0.86
Sex differences in forced-swim and open-field test behaviours after chronic administration of melatonin. Eur J Pharmacol (2000) 0.85
Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine. Psychopharmacology (Berl) (2007) 0.84
Hippocampal synapsin I, growth-associated protein-43, and microtubule-associated protein-2 immunoreactivity in learned helplessness rats and antidepressant-treated rats. Neuroscience (2006) 0.84
Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse (2009) 0.83
Regulation of cytoskeleton machinery, neurogenesis and energy metabolism pathways in a rat gene-environment model of depression revealed by proteomic analysis. Neuroscience (2010) 0.83
Differential evolution of PSA-NCAM expression during aging of the rat telencephalon. Neurobiol Aging (2007) 0.82
Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J Neurochem (2008) 0.82
Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl) (2010) 0.82
Melatonin affects the immobility time of rats in the forced swim test: the role of serotonin neurotransmission. Eur Neuropsychopharmacol (2006) 0.81
Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J Neurosci Res (2009) 0.81
Microtubule disruption and cognitive defects: effect of colchicine on learning behavior in rats. Pharmacol Biochem Behav (1991) 0.80
Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats. Eur Neuropsychopharmacol (2009) 0.80
Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background. Int J Neuropsychopharmacol (2010) 0.78
Effects of fluoxetine on hippocampal-dependent and hippocampal-independent learning tasks. Behav Pharmacol (2007) 0.78
Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin (2010) 0.78
Effects of long-term treatment with desipramine on microtubule proteins in rat cerebral cortex. Eur J Pharmacol (1997) 0.78
Fluoxetine enhances memory processing in mice. Psychopharmacology (Berl) (1987) 0.78
Melatonin attenuates the decrement of dendritic protein MAP-2 immuno-staining in the hippocampal CA1 and CA3 fields of the aging male rat. Neurosci Lett (2008) 0.78
Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge. Int J Neuropsychopharmacol (2010) 0.77
Serotonin mediates CA1 spine density but is not crucial for ovarian steroid regulation of synaptic plasticity in the adult rat dorsal hippocampus. Synapse (2002) 0.77
Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence. J Pineal Res (2008) 0.75
Effects of fluvoxamine on the protein phosphorylation system associated with rat neuronal microtubules. Eur Neuropsychopharmacol (1995) 0.75
cAMP binding proteins in the rat cerebral cortex after administration of selective 5-HT and NE reuptake blockers with antidepressant activity. Neuropsychopharmacology (1991) 0.75
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry (2006) 1.53
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov (2010) 1.47
Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology (2010) 1.31
Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem (2003) 1.17
Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse (2003) 1.06
Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem J (2004) 1.04
Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology (2009) 1.01
Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology (2002) 1.01
Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol (2009) 1.01
The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology (2009) 0.98
Akt-dependent expression of NAIP-1 protects neurons against amyloid-{beta} toxicity. J Biol Chem (2005) 0.98
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther (2007) 0.94
Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Mol Cell Neurosci (2002) 0.93
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci (2004) 0.91
Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology (Berl) (2011) 0.90
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol (2006) 0.89
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.89
Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry (2010) 0.88
The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol (2008) 0.87
Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behav Brain Res (2010) 0.87
Structural abnormalities of the coronary arterial wall--in addition to luminal narrowing--affect myocardial blood flow reserve. J Nucl Med (2011) 0.87
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol (2005) 0.87
Graphene audio voltage amplifier. Small (2012) 0.86
Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol Biochem Behav (2011) 0.86
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol (2006) 0.86
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology (2004) 0.84
Inverse association between circulating levels of soluble receptor for advanced glycation end-products and coronary plaque burden. J Atheroscler Thromb (2012) 0.83
Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl) (2010) 0.82
The effects of antidepressant treatment in prenatally stressed rats support the glutamatergic hypothesis of stress-related disorders. J Neurosci (2014) 0.82
Gigahertz integrated graphene ring oscillators. ACS Nano (2013) 0.82
The antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala. Brain Res (2012) 0.82
Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats. Int J Neuropsychopharmacol (2012) 0.81
Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain. J Neurosci Res (2011) 0.80
Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression. Pharmacol Biochem Behav (2011) 0.80
Cascading wafer-scale integrated graphene complementary inverters under ambient conditions. Nano Lett (2012) 0.79
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006. Eur J Pharmacol (2011) 0.79
Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes. BMC Neurosci (2013) 0.78
Like melatonin, agomelatine (S20098) increases the amplitude of oscillations of two clock outputs: melatonin and temperature rhythms. Chronobiol Int (2013) 0.78
Modulatory effects of S 38232, a non alpha-7 containing nicotine acetylcholine receptor agonist on network activity in the mouse hippocampus. Neuropharmacology (2009) 0.78
The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci Ther (2010) 0.78
Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology (Berl) (2003) 0.78
Prevalence of thyroid dysfunction and effect of contrast medium on thyroid metabolism in cardiac patients undergoing coronary angiography. Acta Radiol (2012) 0.77
Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers. J Clin Psychopharmacol (2011) 0.76
Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence. Pain (2017) 0.75
[Low T3 syndrome and left ventricular diastolic function]. G Ital Cardiol (Rome) (2009) 0.75
First evidence of melatonin receptors distribution in the suprachiasmatic nucleus of tree shrew brain. Neuro Endocrinol Lett (2007) 0.75
Agomelatine: a new opportunity to reduce neuropathic pain. Preclinical evidence. Pain (2016) 0.75
[Heart failure and cholelithiasis]. Recenti Prog Med (2006) 0.75
Suspended monolayer graphene under true uniaxial deformation. Nanoscale (2015) 0.75
Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin. Therapie (2008) 0.75
[Paget-Schroetter disease: clinical and therapeutic considerations]. Chir Ital (2002) 0.75
Aortopulmonary fistula after a modified Bentall procedure. J Heart Valve Dis (2012) 0.75
[Treatment of acute biliary pancreatitis: our experience]. Chir Ital (2004) 0.75
Contrast medium nephrotoxicity after renal artery and coronary angioplasty. Acta Radiol (2010) 0.75
Kaledo, a board game for nutrition education of children and adolescents at school: cluster randomized controlled trial of healthy lifestyle promotion. Eur J Pediatr (2014) 0.75
[Report of a case of Gardner's syndrome: clinical and epidemiologic considerations and review of the literature]. Chir Ital (2003) 0.75